Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more
Abivax SA (ABVX) - Net Assets
Latest net assets as of September 2025: €511.24 Million EUR
Based on the latest financial reports, Abivax SA (ABVX) has net assets worth €511.24 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€652.05 Million) and total liabilities (€140.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €511.24 Million |
| % of Total Assets | 78.4% |
| Annual Growth Rate | 1.62% |
| 5-Year Change | 768.48% |
| 10-Year Change | -43.43% |
| Growth Volatility | 2962.31 |
Abivax SA - Net Assets Trend (2013–2024)
This chart illustrates how Abivax SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Abivax SA (2013–2024)
The table below shows the annual net assets of Abivax SA from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €40.58 Million | -79.29% |
| 2023-12-31 | €196.01 Million | +10314.98% |
| 2022-12-31 | €1.88 Million | -93.46% |
| 2021-12-31 | €28.77 Million | +515.75% |
| 2020-12-31 | €4.67 Million | -60.33% |
| 2019-12-31 | €11.78 Million | -66.00% |
| 2018-12-31 | €34.65 Million | -28.07% |
| 2017-12-31 | €48.18 Million | -15.05% |
| 2016-12-31 | €56.72 Million | -20.94% |
| 2015-12-31 | €71.74 Million | +111.40% |
| 2014-12-31 | €33.94 Million | -0.25% |
| 2013-12-31 | €34.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Abivax SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43887898963.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €633.00K | 1.56% |
| Other Comprehensive Income | €-75.00K | -0.18% |
| Other Components | €478.90 Million | 1180.03% |
| Total Equity | €40.58 Million | 100.00% |
Abivax SA Competitors by Market Cap
The table below lists competitors of Abivax SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dixon Technologies (India) Limited
NSE:DIXON
|
$3.97 Billion |
|
HUB24 Ltd
AU:HUB
|
$3.97 Billion |
|
NKT A/S
PINK:NRKBF
|
$3.97 Billion |
|
Zhejiang Dahua Technology Co Ltd
SHE:002236
|
$3.97 Billion |
|
UPL Limited
NSE:UPL
|
$3.97 Billion |
|
Telephone and Data Systems Inc
NYSE:TDS
|
$3.97 Billion |
|
Texas Capital Bancshares Inc
NASDAQ:TCBI
|
$3.96 Billion |
|
Shenzhen Transsion Holdings Co Ltd
SHG:688036
|
$3.96 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abivax SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 196,010,000 to 40,584,000, a change of -155,426,000 (-79.3%).
- Net loss of 176,242,000 reduced equity.
- Share repurchases of 434,000 reduced equity.
- New share issuances of 434,000 increased equity.
- Other comprehensive income decreased equity by 187,000.
- Other factors increased equity by 21,003,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-176.24 Million | -434.26% |
| Share Repurchases | €434.00K | -1.07% |
| Share Issuances | €434.00K | +1.07% |
| Other Comprehensive Income | €-187.00K | -0.46% |
| Other Changes | €21.00 Million | +51.75% |
| Total Change | €- | -79.29% |
Book Value vs Market Value Analysis
This analysis compares Abivax SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 170.26x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 29.87x to 170.26x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | €3.67 | €109.60 | x |
| 2014-12-31 | €4.91 | €109.60 | x |
| 2015-12-31 | €7.37 | €109.60 | x |
| 2016-12-31 | €5.83 | €109.60 | x |
| 2017-12-31 | €4.85 | €109.60 | x |
| 2018-12-31 | €3.39 | €109.60 | x |
| 2019-12-31 | €0.97 | €109.60 | x |
| 2020-12-31 | €0.33 | €109.60 | x |
| 2021-12-31 | €1.72 | €109.60 | x |
| 2022-12-31 | €0.38 | €109.60 | x |
| 2023-12-31 | €4.55 | €109.60 | x |
| 2024-12-31 | €0.64 | €109.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abivax SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -434.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1633.08%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 5.06x
- Recent ROE (-434.26%) is below the historical average (-226.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -17.32% | -7871.50% | 0.00x | 1.13x | €-9.30 Million |
| 2014 | -14.97% | -7566.96% | 0.00x | 1.12x | €-8.47 Million |
| 2015 | -22.24% | -6997.81% | 0.00x | 1.06x | €-23.13 Million |
| 2016 | -25.23% | -9475.50% | 0.00x | 1.07x | €-19.98 Million |
| 2017 | -23.29% | -3152.25% | 0.01x | 1.12x | €-16.04 Million |
| 2018 | -45.66% | -1941.47% | 0.02x | 1.56x | €-19.29 Million |
| 2019 | -260.03% | 0.00% | 0.00x | 4.39x | €-31.81 Million |
| 2020 | -803.57% | -268221.43% | 0.00x | 15.26x | €-38.02 Million |
| 2021 | -147.54% | -114735.14% | 0.00x | 3.84x | €-45.33 Million |
| 2022 | -844.90% | -1325.33% | 0.06x | 10.20x | €-61.46 Million |
| 2023 | -75.37% | -3197.14% | 0.01x | 1.67x | €-167.34 Million |
| 2024 | -434.26% | -1633.08% | 0.05x | 5.06x | €-180.30 Million |
Industry Comparison
This section compares Abivax SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $6,361,804
- Average return on equity (ROE) among peers: -54.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abivax SA (ABVX) | €511.24 Million | -17.32% | 0.28x | $3.97 Billion |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.57 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.01 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $424.10K |